MultiVita: A Name Ten Companies Share, and What That Does to a Search

Search the Korean drug register for products whose name contains 멀티비타 and twelve licences come back. They are held by ten different companies. Four are injections, and the rest are soft capsules, chewable tablets, an oral liquid and a plain tablet. Two of them are children's products. One of them is the prescription injectable a distributor means when they say MultiVita, and the register offers no field that tells you which one anybody is talking about.

Twelve licences, ten companies, five dosage forms

The register entry for a product name is not a trademark record. It records that a licence holder filed a product under that name and that the filing was granted, which means a name can appear as many times as companies choose to use it. MultiVita has been chosen ten times.

Read down the form column and the spread is the striking part. Four injections, three soft capsules, two chewable tablets, two plain tablets and one oral liquid. Those are not close relatives. An injection administered by a professional and a chewable tablet marketed to children are different products in every respect that matters, and the register places them under the same searchable string.

Five of the twelve are no longer live, and the register does not record them all the same way: two were withdrawn and three reached the end of their term. Two of those five are injections. That leaves the injectable side of this name thinner than the count of twelve suggests: two valid injections out of twelve filings, one of them from 2005 and one from 2019.

The pattern of endings within this name is worth one paragraph on its own, because it falls unevenly across the forms and because the register distinguishes two kinds of ending. Two of the four injections filed under this name have ended, both by reaching the end of their term, leaving the 2005 filing and a 2019 one. On the oral side, three of eight have ended, two of them withdrawn outright. A buyer working from a list of twelve, or from a supplier's assurance that many MultiVita products are licensed in Korea, is reading a population in which the injectable segment has thinned considerably. What a withdrawal means for any individual filing is not recorded, and we have written elsewhere about why that blank should be left blank rather than filled with a guess.

The name is also doing something a brand normally does not. 멀티비타 reads in Korean as a compound of multi and vitamin, which is a description of contents rather than an invented mark. Companies did not converge on it by coincidence. They each reached for the ordinary words for what the product is, which is exactly why ten of them landed in the same place.

What a shared name does to a register lookup

The verification routine most buyers are taught is to search the register for the product name and confirm that it comes back valid. Run that routine on MultiVita and it succeeds, twelve times, and tells you almost nothing.

A supplier can say truthfully that MultiVita is a licensed Korean product. They can say it while pointing at a children's chewable tablet. The statement holds and the meaning does not transfer, which is the same structural failure we described for hyaluronate lookups where a query returns a large population that is mostly eye medicine, set out in two names for hyaluronic acid. Here the population is smaller and the failure is sharper, because the twelve results are not variations of one product type. They are five different dosage forms.

What narrows it is the licence holder. The product KSTATION supplies as MultiVita Inj is manufactured by Daehan New Pharm, and the register carries exactly one filing matching that combination of name and holder: 멀티비타주, granted 13 June 2005 and currently valid. Name plus holder resolves to a single row where name alone resolves to twelve.

That is the general repair for a shared name, and it costs one extra question. Ask who holds the licence, not only whether a licence exists. A supplier who can answer is reading a document. A supplier who cannot has told you they are working from a carton or a catalogue entry rather than from a filing.

The same collision shows up in search

What makes MultiVita worth an article rather than a footnote is that the register is not the only place this happens. The identical pattern appears in how people search for it, and the numbers are ours to read.

Over the twenty-eight days to 31 August 2026, the query multivita brought our pages 1,104 impressions at an average position of 5.6 and a click-through rate of 0.36 percent. The query multivita inj, on the same page, ran at 11.5 percent. Same product, same ranking neighbourhood, and a thirty-fold difference in whether anyone clicks.

The reading is not that our page is bad at one query and good at the other. It is that the two queries are being typed by different people. Someone searching multivita is very often looking for a multivitamin, in the ordinary sense that ten Korean companies also reached for, and a professional injectable is not what they wanted. Someone searching multivita inj has already narrowed to the injection and finds what they were after.

This is the search-side twin of the register problem, and it has a practical consequence for anyone sourcing. When a product name is close to a generic description, both the regulatory record and the search index will return a mixed population, and the discipline that resolves one resolves the other: add a qualifier that only the product you mean would carry. For the register that qualifier is the licence holder. For a search it is the form.

There is a further wrinkle in how the two queries behave. Position is nearly the same for both, which rules out the simplest explanation. If our page ranked poorly on the generic query and well on the specific one, the click gap would need no further account. It ranks in the same neighbourhood on both, which means the difference is happening after the result is seen rather than before. People are looking at the result and deciding it is not what they wanted, thirty times more often on one query than the other.

It also explains a pattern buyers notice and misread. A product whose name is nearly generic will look like it has enormous search demand and poor conversion, and the temptation is to conclude that the listing needs work. Often the listing is fine and the query is simply not about the product.

What MultiVita Inj declares on its own terms

Set the name aside and the product itself is straightforward to describe. MultiVita Inj is supplied as ten vials of 4mL, manufactured by Daehan New Pharm, and presented as a blended vitamin preparation for professional use. It sits in the drug register rather than the device register, which means it carries the fields a drug filing carries: a licence number, a holder, a grant date and a supply classification.

Being a blend is the part that most affects how it should be read. A single-active injectable can be searched by its active ingredient and matched against a population, which is what makes an ascorbic acid product tractable to verify. A blended preparation has several declared components, and no single ingredient query returns it cleanly, because each component appears in hundreds or thousands of unrelated filings. Thiamine alone appears in 657 Korean filings and pyridoxine in 1,119, and neither number tells you anything about this product.

So the verification path for a blend runs through the product filing rather than through the ingredient index. Name plus holder, then the licence itself. This is the opposite of the route we recommended for single-active products in reading an injectable vitamin C, and the difference is worth holding onto: the right lookup depends on whether the product is one thing or several.

The wider point about what a licence count can and cannot tell you about a vitamin product is set out in what 840 licences do not tell you, which reads the same register from the ingredient side.

Why a near-generic name is a sourcing risk rather than a branding one

It would be easy to file this under marketing and move on. A company chose a descriptive name, competitors did the same, and the result is a crowded index. That framing misses where the cost actually lands.

The cost lands on identification. Every control a buyer applies to a cross-border purchase depends on being able to say which product is being bought: the register check, the invoice, the customs description, the batch record, the reorder six months later. A name that resolves to twelve filings weakens all of them at once, and it does so silently, because each individual document looks complete. An invoice reading MultiVita is a valid invoice. It is simply not an identification.

The failure mode is not usually deliberate substitution. It is drift. A catalogue entry gets written once, a reorder references the catalogue rather than the original filing, a new staff member reads the catalogue, and three steps later the chain no longer contains the licence holder anywhere. Nobody lied and the identifier is gone.

Which is why the repair belongs in the record rather than in the conversation. Writing the licence holder and the Korean product name into the order record costs nothing at the time and is the only thing that makes the purchase re-identifiable later. This is the same discipline that applies to recording a register status with its date, and for the same reason: a note that captures what was observed survives, while a note that captures an impression does not.

Identifying which MultiVita a supplier means

Four questions settle it, and they take one message.

Ask for the licence holder by name. This alone reduces twelve filings to one in this case, and it is the single most efficient question available on any shared name.

Ask for the dosage form in the supplier's own words. A supplier quoting the injection will say injection without prompting. One who answers with a general description of a vitamin product may be quoting from a catalogue that does not distinguish the forms, and that is worth knowing before an order rather than after.

Ask for the licensed product name in Korean rather than the romanised trade name. The Korean name is what the register holds, and it carries the form inside it, which is why 멀티비타주 and 멀티비타정 are visibly different strings while both romanise toward MultiVita.

Confirm the presentation against the quote. Ten vials of 4mL is the presentation we stock, and container count and volume are the fields a mismatched shipment fails first.

There is a fifth question that only applies when the answers to the first four do not line up. If a supplier names a holder that does not appear against this product name in the register, that is not necessarily evidence of anything wrong, because contract manufacturing and distribution arrangements can put more than one company name on a supply chain. What it does mean is that the register no longer confirms the chain on its own, and the next document to ask for is the one that connects the two names. A supplier who can produce it has answered. A supplier who treats the question as unusual has told you how far their own visibility extends.

None of these four asks the supplier to prove anything unusual. They are the ordinary contents of a product filing, and a supply chain with access to the filing produces them without difficulty.

Sourcing MultiVita, and the neighbouring products

KSTATION stocks MultiVita Inj in the ten vial presentation, sourced through official Korean channels, with the manufacturer named on the listing rather than left to the brand name. For a category where the name resolves to twelve filings, naming the holder is not a detail. It is the identifying field.

Buyers comparing across this part of the range will also encounter CINDELLA Inj and VITAMIN C Inj, which sit in the same vitamins and injectables collection and are read differently from one another: one is a blend, one is a single active with a large ingredient population behind it. The reading routine differs accordingly, and treating them as interchangeable because they share a shelf produces the same category error the shared name produces.

One point of caution when comparing quotes across suppliers for this product. Because several filings share the name and the forms differ, a price that looks unusually favourable may be quoting a different form entirely rather than a better deal on the same one. The check is the same as everywhere else in this article: resolve the quote to a filing before comparing it to anything.

On arrival, confirm the vial count and volume, confirm that the carton names the manufacturer, and keep the licensed product name with the order record rather than only the romanised one. A note reading "MultiVita Inj, Daehan New Pharm, 멀티비타주, 4mL x 10" is unambiguous six months later. A note reading "MultiVita" is a name that ten companies share.

Shipping arrangements for this category, including the duties-paid option available on United States orders, are set out on the shipping options page.

Sources and references

• Ministry of Food and Drug Safety (MFDS), Korean drug product licence register, product name query 멀티비타 (12 filings, 7 valid) and active ingredient queries Thiamine (657) and Pyridoxine (1,119), retrieved 3 September 2026.
• Manufacturer-declared specifications for MultiVita Inj (4mL x 10 vials), read 3 September 2026.
• Google Search Console, KSTATION property, query-level data for the 28 days to 31 August 2026.
• KSTATION editorial policy.